Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 4/20 | 0.37 |
| ▸ | POLH | Q9Y253 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.33 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16981072 | 0.79 | ALDH1A1 (0.39) | ADORA3ALDH2CYP3A4ALDH1A1MAPT | |
| SCHEMBL14134418 | 0.79 | ADORA3 (0.32) | ALOX5ADORA3ALDH2 | |
| SCHEMBL27554470 | 0.79 | ALDH1A1 (0.48) | ALOX5ADORA3CYP3A4ALDH1A1CYP2C9 | |
| SCHEMBL12249331 | 0.75 | KDM4E (0.31) | ALOX5CYP2C19 | |
| SCHEMBL31259502 | 0.65 | POLH (0.46) | ALOX5POLHESR1ESR2CYP3A4 | |
| SCHEMBL16576817 | 0.63 | KDM4E (0.30) | MAPT | |
| SCHEMBL16576812 | 0.63 | MCL1 (0.43) | ALDH1A1KMT2A | |
| SCHEMBL27401513 | 0.62 | ALDH1A1 (0.43) | ADORA3CYP3A4ALDH1A1CYP2C9TSHR | |
| SCHEMBL14029548 | 0.62 | TSHR (0.31) | TSHR | |
| SCHEMBL31155758 | 0.62 | KDM4E (0.40) | ESR1ESR2ALDH2CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080026076-A1 | Quercetin supplementation to treat hypertension | JALILI THUNDER | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080026076-A1 | Quercetin supplementation to treat hypertension | FABP3, SLC5A6, REN | ALOX5 166/4885POLH 1996/4885ADORA3 2933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.